NCT01942083终止1 期
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 33
- 主要终点
- Safety of OPB-111077
研究概览
简要总结
This is a Phase I, open label, non randomized, multicenter study designed to investigate the safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in subjects with advanced HCC.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histopathologically or clinically diagnosed HCC by Korean Liver Cancer Study Group (KLCSG) guidelines.
- •Subject who has advanced HCC
- •Documented evidence of unresponsiveness to, intolerance to, or ineligibility for sorafenib, or unavailability of appropriate sorafenib treatment
- •Male or female subject, age at consent ≥20 years and ≤75 years.
- •Life expectancy ≥12 weeks.
- •Subjects who agree that they or their partner(s) will practice contraception during the study period and 3 months (12 weeks) after the completion of study treatment.
- •Subjects informed of the diagnosis of advanced HCC who are fully informed about the content of the study by the Investigator using the written consent form, and give written consent to participate in the study of their own free will.
排除标准
- •Past liver transplantation
- •Uncontrollable hepatic encephalopathy or ascites
- •Presence of brain metastases
- •Clinically significant gastrointestinal bleeding in past 6 months or current active gastrointestinal bleeding.
- •Primary malignancy other than HCC
- •Human immunodeficiency virus (HIV) infection
- •Severe or poorly controlled complication that may affect the conduct or results of the study.
- •Use of Interferon preparation within 4 weeks (28 days) before start of study treatment in the present study.
- •Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant during the study period
- •Other cases judged by the Investigator to be ineligible for participation in the study.
研究组 & 干预措施
OPB-111077
Experimental
orally, once daily
干预措施: OPB-111077 (Drug)
结局指标
主要结局
Safety of OPB-111077
时间窗: Within the first cycle [24 days]
Number of participants with adverse events as assessed by CTCAE v4.0
To investigate the maximum tolerated dose (MTD) of OPB-111077
时间窗: Within the first cycle [24 days]
• The highest dose that does not lead to discontinuation of dose escalation is defined as the MTD.
次要结局
- Pharmacokinetics (PK) properties of OPB-111077 and its metabolites.(Within the first cycle [24 days])
- Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1(Approximately 3-18 weeks depending on tumor response)
- Biomarker of OPB-111077(Within the first cycle [24 days])
研究者
相似试验
招募中
1 期
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic MalignanciesAdvanced Solid Tumors and Hematologic MalignanciesNCT05690581Beijing InnoCare Pharma Tech Co., Ltd.146
终止
1 期
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung CancerSmall Cell Lung CarcinomaNCT01187615Bayer9
已完成
1 期
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)Nosocomial PneumoniaNCT04223752Merck Sharp & Dohme LLC41
已完成
1 期
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentNon-Small-Cell Lung CarcinomaNCT01801111Hoffmann-La Roche138
招募中
1 期
A Study of HS248 in Patients With Advanced Solid TumorsSolid Tumor, AdultNCT05759234Hanhui Pharmaceutical Co., Ltd24